Natriumvalproaat Chrono Cf (Valproic Acid, Sodium Valproate)

Valproic acid, the active ingredient in Natriumvalproaat Chrono Cf, is an Anticonvulsant presented as an oral formulation for systemic use. It is employed to manage seizure disorders, mood stabilization in bipolar disorder, and migraine prevention in adult patients.

GNH USA supplies Natriumvalproaat Chrono Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Valproic acid is an anticonvulsant that modulates neuronal excitability across several neurological and psychiatric conditions.

- Epilepsy: reduces the frequency and severity of generalized and focal seizures. - Bipolar disorder: stabilises mood and prevents manic or depressive episodes. - Migraine prophylaxis: decreases the occurrence of migraine attacks when used as a preventive therapy.

Adverse reactions can range from mild to severe, depending on individual susceptibility and treatment duration.

Common Side Effects: - Nausea or gastrointestinal upset. - Tremor or mild motor incoordination. - Weight gain or increased appetite. - Drowsiness or fatigue.

Serious or Rare Side Effects: - Hepatic failure or severe liver enzyme elevation. - Pancreatitis with abdominal pain and elevated enzymes. - Severe skin reactions such as Stevens‑Johnson syndrome. - Thrombocytopenia or significant drop in platelet count. - Hyperammonemia leading to encephalopathy. - Suicidal thoughts or behavior.

Valproic acid requires careful monitoring and patient counseling due to its safety profile.

- Pregnancy: contraindicated (Category X) because of high teratogenic risk. - Liver function: assess baseline and periodic liver enzymes, especially in the first six months. - Hematology: monitor complete blood count for thrombocytopenia or leukopenia. - Drug interactions: avoid concurrent use with strong enzyme inducers without dose adjustment. - Alcohol: advise patients to limit alcohol intake to reduce hepatotoxic risk. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Valproic acid participates in several clinically significant drug interactions.

Major Interactions (Avoid): - Carbamazepine, phenytoin, phenobarbital: potent enzyme inducers that lower valproate levels. - Warfarin: increased anticoagulant effect may lead to bleeding. - Other anticonvulsants that share hepatic metabolism pathways.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced hormonal efficacy, consider alternative contraception. - Aspirin and other NSAIDs: may increase risk of gastrointestinal bleeding. - Lamotrigine: requires dose adjustment to avoid severe skin reactions. - Antidepressants (e.g., SSRIs): monitor for additive CNS depression.